ArticleAntimicrobial agents and chemotherapy2003
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 61 citations in OpenAlex.
- Impact of Anti-Mycotic Drugs on the Osteogenic Response of Bone Marrow Mesenchymal Stem Cells In Vitro.Antibiotics (Basel, Switzerland) · 2024Article
- Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.Scientific reports · 2020Article
- Enhanced AmB Production inFrontiers in bioengineering and biotechnology · 2020Article
- Nanostructured delivery systems with improved leishmanicidal activity: a critical review.International journal of nanomedicine · 2017Review
- Metabolomics as a tool to evaluate the toxicity of formulations containing amphotericin B, an antileishmanial drug.Toxicology research · 2016Article
- Development of novel docetaxel phospholipid nanoparticles for intravenous administration: quality by design approach.AAPS PharmSciTech · 2015Article
- Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.BMC infectious diseases · 2015Article
- Properties of An Oral Nanoformulation of A Molecularly Dispersed Amphotericin B Comprising A Composite Matrix of Theobroma Oil and Bee'S Wax.Nanomaterials (Basel, Switzerland) · 2014Article
- In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum.Antimicrobial agents and chemotherapy · 2014Article
- Central nervous system toxicity associated with liposomal amphotericin B therapy for cutaneous leishmaniasis.The American journal of tropical medicine and hygiene · 2011Article
- Beyond oncology--application of HPMA copolymers in non-cancerous diseases.Advanced drug delivery reviews · 2010Review
- Nanocarriers' entry into the cell: relevance to drug delivery.Cellular and molecular life sciences : CMLS · 2009Review
- N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents.International journal of antimicrobial agents · 2009Article
- Leishmaniasis treatment--a challenge that remains: a review.Parasitology research · 2008Review
- Amphotericin B-gum arabic conjugates: synthesis, toxicity, bioavailability, and activities against Leishmania and fungi.Pharmaceutical research · 2007Article
- Activities of naphthylisoquinoline alkaloids and synthetic analogs against Leishmania major.Antimicrobial agents and chemotherapy · 2007Article
- Optimizing efficacy of Amphotericin B through nanomodification.International journal of nanomedicine · 2007Review
- Nanotechnology: intelligent design to treat complex disease.Pharmaceutical research · 2006Review
- Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.Antimicrobial agents and chemotherapy · 2005Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to evaluate the toxicity and the activity of a new lipid complex formulation of amphotericin B (AMB) (LC-AMB; dimyristoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, and AMB) that can be produced by a simple process. Like other lipid formulations, this new complex reduced both the hemolytic activity of AMB (the concentration causing 50% hemolysis of human erythrocytes, >100 microg/ml) and its toxicity toward murine peritoneal macrophages (50% inhibitory concentration, >100 microg/ml at 24 h). The in vivo toxicity of the new formulation (50% lethal dose, >200 mg/kg of body weight for CD1 mice) was similar to those of other commercial lipid formulations of AMB. The complex was the most effective formulation against the DD8 strain of Leishmania donovani. It was unable to reverse the resistance of an AMB-resistant L. donovani strain. In vivo LC-AMB was less efficient than AmBisome against L. donovani.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.